Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...

Moleculin Biotech, Inc., ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it ...

Maintaining optimal dental health is crucial for overall well-being, and in today’s fast-paced world, effective solutions are ...